Tumor hypoxia is often found in many human cancers; their presence has been implicated in radio- and chemo-resistance, a more aggressive phenotype, and is an important prognostic factor of treatment outcome. The long term goal of this proposal is to develop an image-guided therapeutic strategy, combining hypoxia imaging, radiotherapy and gene therapy, to overcome hypoxia-mediated radioresistance and improve cancer cure. The major facets of this strategy are 1) the imaging and localization of tumor hypoxia, 2) image-guided delivery of vectors that express a radiosensitizing effector gene as well as a hypoxia-induced marker gene, 3) verification of vector delivery to hypoxic cells by molecular imaging, and 4) tumor eradication by radiation. To evaluate and validate this approach, there are three Specific Aims:
In Specific Aim I, we shall design and construct vectors that express both a marker gene HSV1-tk from a hypoxia-inducible promoter and an effector gene that antagonizes the repair of DNA breaks, and use them to stably transfect tumor cell lines. The degree of radiosensitization of tumor cells that constitutively or inducibly express various effector genes will be assessed in vitro and in vivo; the specific expression of the viral tk gene in hypoxic cells will be evaluated by microPET imaging of TK-mediated trapping of 124I-FIAU in tumors transplanted in nude mice.
In Specific Aim II, replication defective adenovirus containing the hypoxia marker gene and the effector gene will be constructed. The efficacy of adenovirus-mediated delivery of the marker gene and the effector gene, the hypoxia inducibility of the marker tk gene, and the radiosensitizing effect of the effector gene will then be studied in vitro and in vivo.
In Specific Aim III, we shall transplant rodent and human tumors into nude rats, identify and localize the hypoxic sub-volume using microPET/18F-FMISO imaging. Guided by these images, adenoviral vectors will be delivered to the hypoxic region of the tumor and microPET imaging based on TK-mediated trapping of 124I-FIAU will be used to verify the preferential delivery of the vectors to hypoxic cells. The tumor's response to radiation will then be evaluated. In pilot studies, we have shown that antisense Ku70 or a dominant negative Ku70 fragment significantly radiosensitizes hypoxic tumor cells in vitro and in vivo, and that they can be successfully delivered into tumors by adenoviral vectors. For tumor hypoxia targeting, we have implemented microPET imaging with 18F-FMISO and developed a stereotaxic template for guiding adenoviral vector injection. Also, we have shown that the hypoxia-induction of the marker tk gene can be readily detected using 124I-FIAU / microPET in vivo. The information gained from the proposed preclinical studies will serve as a guide in the design of clinical strategy to improve the outcome of cancer therapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory/Developmental Grants Phase II (R33)
Project #
5R33CA109772-03
Application #
7231940
Study Section
Special Emphasis Panel (ZRG1-SBIB-J (90))
Program Officer
Bernhard, Eric J
Project Start
2005-05-01
Project End
2011-04-30
Budget Start
2007-05-01
Budget End
2011-04-30
Support Year
3
Fiscal Year
2007
Total Cost
$540,153
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Dong, Jun; Ren, Yufeng; Zhang, Tian et al. (2018) Inactivation of DNA-PK by knockdown DNA-PKcs or NU7441 impairs non-homologous end-joining of radiation-induced double strand break repair. Oncol Rep 39:912-920
Dong, Jun; Zhang, Tian; Ren, Yufeng et al. (2017) Inhibiting DNA-PKcs in a non-homologous end-joining pathway in response to DNA double-strand breaks. Oncotarget 8:22662-22673
Sun, Xiaorong; Ackerstaff, Ellen; He, Fuqiu et al. (2015) Visualizing the antivascular effect of bortezomib on the hypoxic tumor microenvironment. Oncotarget 6:34732-44
Hsiao, Hung Tsung; Xing, Ligang; Deng, Xuelong et al. (2014) Hypoxia-targeted triple suicide gene therapy radiosensitizes human colorectal cancer cells. Oncol Rep 32:723-9
Xing, L; Sun, X; Deng, X et al. (2013) A triple suicide gene strategy that improves therapeutic effects and incorporates multimodality molecular imaging for monitoring gene functions. Cancer Gene Ther 20:358-65
Urano, Muneyasu; Li, Gloria C; He, Fuqiu et al. (2012) The effect of DN (dominant-negative) Ku70 and reoxygenation on hypoxia cell-kill: evidence of hypoxia-induced potentially lethal damage. Int J Radiat Biol 88:515-22
Sun, Xiaorong; Xing, Ligang; Deng, Xuelong et al. (2012) Hypoxia targeted bifunctional suicide gene expression enhances radiotherapy in vitro and in vivo. Radiother Oncol 105:57-63
Urano, Muneyasu; He, Fuqiu; Minami, Akiko et al. (2010) Response to multiple radiation doses of human colorectal carcinoma cells infected with recombinant adenovirus containing dominant-negative Ku70 fragment. Int J Radiat Oncol Biol Phys 77:877-85
Sun, Xiaorong; Xing, Ligang; Ling, C Clifton et al. (2010) The effect of mild temperature hyperthermia on tumour hypoxia and blood perfusion: relevance for radiotherapy, vascular targeting and imaging. Int J Hyperthermia 26:224-31
Xing, Ligang; Sun, Xiaorong; Deng, Xuelong et al. (2009) Expression of the bifunctional suicide gene CDUPRT increases radiosensitization and bystander effect of 5-FC in prostate cancer cells. Radiother Oncol 92:345-52

Showing the most recent 10 out of 14 publications